1 Detection of Circulating Tumor-specific DNA Methylation Markers in the Blood of

2 Patients with Pituitary Tumors.

- 3 Michael Wells^{1,2}, Karam P. Asmaro^{1,2}, Thais S. Sabedot^{1,2}, Tathiane M. Malta^{1,2},
- 4 Maritza S. Mosella^{1,2}, Kevin Nelson¹, James Snyder^{1,2}, Ana deCarvalho¹, Abir
- 5 Mukherjee ³, Dhananjay Chitale ³, Adam Robin ¹, Mark Rosenblum ¹, Thomas
- 6 Mikkelsen¹, Laila M. Poisson⁴, Ian Y. Lee¹, Tobias Walbert¹, Arti Bhan⁶, Steven
- 7 Kalkanis¹, Jack Rock¹, Houtan Noushmehr^{1,2}, Ana Valeria Castro^{1,2*}
- ¹Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health
- 9 System, Detroit, MI, USA
- ²Department of Neurosurgery, Omics Laboratory, Henry Ford Health System, Detroit,
- 11 MI, USA
- 12 ³Department of Pathology, Henry Ford Health System, Detroit, MI, USA
- ⁴Department of Biostatistics, Henry Ford Health System, Detroit, MI, USA
- 14 ⁵Department of Radiology, Henry Ford Health System, Detroit, MI, USA
- ⁶Department of Endocrinology, Henry Ford Health System, Detroit, MI, USA

16 ***Corresponding author**

- 17 Ana Valeria B. Castro, MD, PhD
- 18 Department of Neurosurgery
- 19 Hermelin Brain Tumor Center; Henry Ford Health System
- 20 2799 West Grand Blvd, E&R 3096
- 21 Detroit, MI, 48202
- 22 acastro1@hfhs.org
- 23

24 Abstract

Genome-wide DNA methylation aberrations are pervasive and associated with 25 26 clinicopathological features across pituitary tumors (PT) subtypes. The feasibility to detect 27 CpG methylation abnormalities in circulating cell-free DNA (cfDNA) has been reported in 28 central nervous system tumors other than PT. Here, we aimed to profile and identify 29 methylome-based signatures in the serum of patients harboring PT (n=13). Our analysis 30 indicated that serum cfDNA methylome from patients with PT are distinct from the counterparts in patients with other tumors (gliomas, meningiomas, colorectal carcinomas, 31 32 n=134) and nontumor conditions (n=4). Furthermore, the serum methylome patterns 33 across PT was associated with functional status and adenohypophyseal cell lineage PT 34 subtypes, recapitulating epigenetic features reported in PT-tissue. A machine learning 35 algorithm using serum PT-specific signatures generated a score that distinguished PT 36 from non-PT conditions with 100% accuracy in our validation set. These preliminary 37 results underpin the potential clinical application of a liquid biopsy-based DNA methylation 38 profiling as a noninvasive approach to identify clinically relevant epigenetic markers that 39 can be used in the management of PT.

40

41 Word count:

- 42 Title: 15
- 43 Abstract: 154
- 44 Main Text: 2,934
- 45 Methods: 1,272
- 46 References: 53

48 Introduction

Liquid biopsy (LB) is a method used to detect molecular elements (e.g., DNA, RNA, etc.) shed by tumors in biofluids (blood, cerebrospinal fluid etc). Circulating cell-free DNA (cfDNA), specifically the tumor DNA fraction (ctDNA), is thought to originate from cellular death (apoptosis and necrosis) or secretion from live cells, especially from proliferative tissues or tumors ^{1–5}. Blood-based LB has emerged as a reliable and a minimally invasive approach to identify clinically relevant molecular biomarkers from several tumor origins, including from central nervous system (CNS) neoplasms ^{5–8}.

56 In contrast to CNS tumors that are shielded by the blood-brain barrier, the pituitary 57 gland presents an anatomical structure that facilitates the spillage of tumor cellular 58 material into the bloodstream, i.e. a fenestrated pituitary portal system and/or an access 59 to the cavernous system. This structural advantage creates an opportunity to profile tumor-specific molecular features of material released from these tumors potentially 60 suitable for clinicopathological application ^{9,10}. Indeed, the feasibility to detect and 61 62 sequence somatic gene variants in ctDNA has recently been reported in PT¹; however, the detection sensitivity of this approach was low in these tumors ¹. The paucity of genetic 63 64 alterations in the pathogenesis of PT such as recurrent somatic mutations may have contributed to these results ^{11–15}. In contrast, genome-wide methylation abnormalities 65 detected in the tissue are knowingly pervasive across PT subtypes ^{13,16–23}. Additionally, 66 67 DNA methylome patterns are tissue- and tumor-specific providing an opportunity to predict the tissue of origin of the tumor through DNA methylation profiling ^{5,20,24,25}. In fact, 68 many studies showed that specific methylome patterns detected in the tissue 69 70 distinguished PT from other CNS tumors and defined discrete methylation subtypes

among different CNS tumors ^{20,26,27}. Additionally, methylation markers presented diagnostic, prognostic and predictive applications in CNS tumors ^{20,26,27}. The feasibility of detecting these tissue- or tumor-specific methylation signatures using a liquid biopsy approach is an emerging field that has not been reported in PT to date.

In this study, we profiled the serum cfDNA methylome derived from patients with PT or other tumors and nontumor conditions. We identify unique methylation signatures in the serum associated with clinicopathological features specific to PT. This proof-ofconcept study paves the way for the potential clinical application of a liquid biopsy as a noninvasive approach to identify and assess relevant epigenetic markers that may be useful in the management of patients with PT.

81 **Results**

82 Characterization of pituitary cell-free DNA methylome

83 cfDNA quantification

Total extracted serum cfDNA quantity, normalized to the genomic size (ng/ml, see Methods), were not significantly different from controls (mean \pm SD, 59.3 \pm 134.2 vs 5 \pm 5.0 ng/ml, respectively; p=.14) or in relation to functional or invasion status in PT (Supplemental Figure 1A).

88 **Deconvolution**

The deconvolution of the serum cfDNA methylome showed that patients harboring PT had higher proportion of bulk pituitary gland signatures compared to the control serum and other CNS conditions (3% higher, p = .05)(Supplemental Figure 1B; Supplemental Table 2).

93 Methylome analysis

The genome-wide mean methylation landscape of the serum cfDNA from patients with PT and non-PT conditions (gliomas, meningiomas, colorectal carcinomas and nontumor conditions) showed that PT segregated into a hypomethylated and a hypermethylated cluster; the latter, shared similar CpG methylation degree with the serum methylome from patients with glioma, meningioma, colorectal cancer and nontumor controls (Figure 1A and 1B).

100 Conducting a supervised analysis between PT and non-PT serum specimens and 101 selecting probes that shared similarities with the matching PT tissue (Supplemental 102 Figure 1D, left), we identified 46 differentially methylated probes (DMP), namely <u>P</u>ituitary 103 <u>T</u>umors-specific <u>E</u>pigenetic-<u>L</u>iquid <u>B</u>iopsy (PeLB) probes, that significantly distinguished 104 both groups (Figure 1B) and distinguished two subgroups across PT (hyper and 105 hypomethylated) (Figure 1C),

106 The two methylation clusters were associated with distinct clinicopathological status, i.e. the hypermethylated cluster was predominantly composed of nonfunctioning, 107 108 mainly encompassed by SF1 lineage and null cell tumors and the hypomethylated with 109 functioning PT mostly comprised of Pit1-lineage tumors (Figure 1 C). As an exception, 110 one lactotroph adenoma/Pit1-lineage segregated with nonfunctioning PT, despite being 111 clinically classified as functioning, and a functioning Tpit1-lineage tumor clustered with 112 nonfunctioning tumors. These results recapitulate the findings in their matching tissue 113 (Supplemental Figure 1E).

cfDNA methylome from patients with PT pituitary-specific epigenetic signatures distinct from other pathological conditions.

116 Overlapped with tumor tissues, PeLB probes clustered with PT tissue and significantly 117 separated PT from other CNS tumor-tissue, confirming PeLB-specificity to PT in an 118 independent cohort (Figure 1D). Taking this feature into account, we developed and 119 cross-validated a score derived from a machine learning (ML) model (repeated 5000 120 times), namely the PeLB score, to predict whether a serum specimen originates from a 121 patient with PT or a non-PT condition (Figures 1E-F). Pituitary-derived serum methylome 122 samples carried the highest values of PeLB score (71-99%), whereas the serum of non-123 PT tumors carried the lowest values (0-45%) (Figure F). The evaluation of the model in 124 the validation sample set showed that the model performed with an accuracy of 100%, 125 taking into account a 50% PeLB cutoff.

126 We also defined serum-based methylation signatures (n=70) accounting for the 127 functional/lineage status of PT (nonfunctioning vs functioning PT) (p < .01, differential 128 mean methylation >.2, FDR < .26), we named functioning-PeLB (Func-PeLB)(Figures 129 2A, Supplemental Figure 1D, right). Harnessing the methylome from matching tissue 130 and publicly available data reporting on the functional status of PT, we observed that a 131 subset of the Func-PeLB probes (overlapped with the 450K platform, used to profile the 132 tissue-methylome of those samples) (n=22 probes) (Supplemental Figure 1D, right), 133 also discriminated the two functional groups at the tissue and respective serum levels 134 (Figure 2B-D)

The CpG probes that distinguished the methylation clusters either in tissue (n=5000) or serum (6000) were most frequently located in open sea regions (67% and 61%, respectively) and gene bodies (61 and 55%, respectively) (Figure 1B, Supplemental Table 2).

139 Discussion

140 Methylome-derived signatures define molecular subtypes that are useful for the diagnosis and prognostication across many tumors ^{13,16–18,20,21,26–29}. Additionally, 141 142 genome-wide DNA methylation patterns are cell-specific either in healthy or tumor specimens ^{5,18,20,24,25,30–32}. The ability to detect methylation signatures and tumor-specific 143 144 abnormalities by the profiling of circulating cell-free DNA (cfDNA) in biofluids (liquid 145 biopsy), such as blood, has been useful for the early detection and surveillance of malignant neoplasms ^{5,33–35}. In relation to CNS tumors, our group has recently reported 146 147 on the feasibility to identify methylation-based markers in serum-derived cfDNA for the diagnosis and prognostication of gliomas and meningiomas ³⁶. Herein, we show that, 148 149 similar to malignant and other CNS tumors, PT releases tumor-related information in the 150 blood that allows the identification of clinically relevant methylation signatures specific to 151 patients with PT, namely PeLB probes (Figure 1A-B; Supplemental Figure 1D). 152 Capitalizing on the specificity of these probes, we used a machine learning approach to 153 generate the PeLB score (Figure 1D-E) to predict the presence of a pituitary tumor using liquid biopsy. We showed that PeLB score performed with a 100% accuracy to predict 154 155 that serum was derived from patients with PT in our validation cohort (Figure 1F). These 156 results remain to be confirmed in an independent cohort of PT-derived, currently 157 unavailable.

In addition, distinct serum DNA methylation landscape, specifically PeLB probes, defined two methylation groups that recapitulated the clinicopathological findings displayed in their matching tissue as reported in other studies ^{13,16–18,20,21} (Figure 1C-D, Supplemental Figure 1E). These serum-derived clusters showed that the

162 hypermethylated group was enriched by nonfunctioning PT mainly originated from SF1 163 and Tpit cell lineages and the hypomethylated set mainly composed of functioning PT 164 mostly originated from Pit-1 cell lineages (Figure 1C, Supplemental Figure 1D). We 165 narrowed down to a subset of PeLB probes (Func-PeLB) that preserved the distinction 166 between both clusters in tumor-tissue specimens as well (Figure 2C, Supplemental 167 Figure 1D). Altogether, these results suggest that PT releases DNA methylation markers 168 in the serum that reflect clinicopathological features such as functional status and 169 adenohypophyseal lineage of these tumors. Confirmation of these findings in a larger and 170 more comprehensive cohort lay the groundwork to the application of PeLB probes as an 171 objective approach to classify PT according to cell-lineage as recommended by the 2017 WHO ³⁷. 172

173 Considering the prognostic value reported in glioma or meningiomas, we surveyed 174 serum-methylation markers specific to the invasion status of PT. Corroborating the 175 findings reported in the tissue, we found slight serum differences between invasive and 176 noninvasive groups (data not shown)^{13,16,17,21}. However, the association of tissue- or 177 serum-derived methylation groups with the criteria that better predict PT with higher risk 178 to progress or recur remains to be elucidated ^{13,18,38-43}.

The application of PeLB score is not intended to replace the standard approaches to diagnose and classify PT which, in most of the cases, is satisfactorily performed by clinical features, hormonal assessment in the blood/urine and on the imaging of the pituitary gland ⁴⁴. However, these results provide evidence that serum cfDNA constitutes a reliable source of clinically relevant tumor-specific epigenetic signatures in PT as observed in other CNS tumors ³⁶. Potentially, the specificity of PeLB probes could be

helpful to distinguish PT from other rare primary or secondary sellar tumors whose
diagnosis by morphologic and immunohistochemical approaches may be challenging,
unavailable and/or inconclusive (e.g. craniopharyngioma variants, lymphoma, metastasis
etc) ^{5,34,45,46}.

189 In conclusion, our results indicate that similar to malignant tumors, PT releases 190 circulating tumor DNA that present specific methylation patterns, recapitulating molecular 191 features detected in PT-tissue (e.g. adenohypophyseal lineage-related). Serum from 192 patients with PT provides tumor-specific methylation signatures that allow the 193 classification of samples into PT subtypes or non-PT groups. Finally, our preliminary 194 results underpin the potential application of methylation profile in the serum-based liquid 195 biopsy as a noninvasive approach to assess clinically relevant epigenetic features useful 196 for clinical purposes in the management of patients (e.g. aggressiveness markers, 197 actionable markers to guide future clinical trials to treat aggressive, resistant or recurrent 198 PT etc).

199 Methods

200 Patients - We conducted a retrospective analysis of a cohort comprised of archival serum 201 and paired tissue (fresh-frozen) from 13 patients who underwent transsphenoidal surgery 202 for the resection of invasive (n=5) or noninvasive (n=8) macroadenomas of different 203 functional status and histological subtypes (9 nonfunctioning: 4 gonadotroph and 5 null 204 cell and 4 functioning: 2 lactotroph, 1 corticotroph and 1 mixed GH/PRL/TSH) (Table 1). 205 Criteria for invasiveness was based on Knosp grades 3-4 (n=4) or invasion of clivus (n=1) ^{47,48}. MRI assessment for size, and invasiveness classification was blindly and 206 independently performed by two physicians from the Henry Ford Health System (HFHS) 207 (TA, KPA). HFHS Pathologists provided a comprehensive pathology report on 208 209 adenohypophyseal immunostaining, necrosis and quantification of markers of proliferation (Ki-67, mitotic counts, p53). Control serum was obtained from patients 210 211 without PT (three epileptic patients and one with a nontumor condition). Control pituitary 212 tissue was obtained from non-neoplastic pituitary harvested at autopsy (FFPE). We also 213 generated serum methylome data from patients with glioma (n=114), meningiomas (n=6) 214 and other CNS conditions (brain metastasis, 1 brain colloid cyst, 6 brain radiation 215 necrosis) (Supplemental Table 2) The project was approved by the HFHS Institutional 216 Review Board (IRB# 10963) and patients consented to have their specimens used for 217 research purposes. Publicly available methylome data from colorectal carcinoma was retrieved (CRC, n= 2 pooled samples) 49. 218

219 Serum collection and processing

For the specimens originated from the HFHS, peripheral blood (15 mL) was drawn from each subject at the time of surgery before the tumor excision (transphenoidal).

Serum sample was separated within 1 hour from collection by centrifugation at 1,300 x g for 10 minutes at 20°C; aliquoted into up to five 2 mL cryovials and stored at -80°C until processing. The methods for the publicly available data is described in their respective manuscripts ⁴⁹

226 DNA isolation, quantification, and DNA methylation data generation

227 Tissue and serum DNA were extracted from 2.2-9.3mL aliquots of serum using the 228 Quick-cfDNA Serum & Plasma Kit according to the manufacturer's protocol (Zymo 229 Research - catalog # D4076). DNA concentration was measured with Qubit (Thermo 230 Fisher Scientific) /or with 4200 TapeStation (Agilent Technologies). The concentration of 231 cfDNA in the serum was calculated by dividing the total amount of cfDNA extracted by the amount of serum used for extraction. We then converted the concentration of cfDNA 232 233 in the serum (ng/mL) into haploid genome equivalents/mL by multiplying by a factor of 303 (assuming the mass of a haploid genome 3.3 pg)⁵⁰. 234

235 The extracted DNA (30-300 ng) was bisulfite-converted (Zymo EZ DNA 236 methylation Kit; Zymo Research) and profiled using an Illumina Human EPIC array (HM850K), at the USC Epigenome Center, Keck School of Medicine, University of 237 Southern California, Los Angeles, California. The raw DNA methylation data reported in 238 239 deposited Mendeley this been Data paper has to at 240 https://data.mendeley.com/datasets/cgrz6zztfg.

241 DNA methylation pre-processing

Methylation array data was processed with the minfi package in R. The raw signal intensities were extracted from the *.IDAT files and corrected for background fluorescence intensities and red-green dye-bias using the function preprocess Noob as

described by Triche et al., 2013 ⁵¹. The beta-values were calculated as (M/(M+U)), in which M and U refer to the (pre-processed) mean methylated and unmethylated probe signal intensities, respectively. Measurements in which the fluorescent intensity was not statistically significant above background signal (detection p value > 10^{-16}) were removed from the data set. Before the analysis, we filtered out probes that were designed for sequences with known polymorphisms or probes with poor mapping quality (complete list of masked probes provided by Zhou et al. ⁵²) and the X and Y chromosomes.

252 **Deconvolution**

We applied a previously described methodology ⁵⁰ to deconvolute the relative 253 contribution of cell types to a given sample ⁵⁰. We included methylation signatures from 254 cell lines, immune cells (B-cell, CD4T, CD8T, natural killer cells and white blood cells 255 256 (monocytes, neutrophils) and vascular endothelial cells ⁵⁰ (Supplemental Table 2) For 257 lack of information related to methylation signatures from individual cells that comprise 258 the pituitary gland, we generated genome-wide methylation signatures from bulk non-259 neoplastic pituitaries obtained from cadavers (unpublished data) and followed the steps for defining the signatures as previously described ⁵⁰. Briefly, we selected the 100 most 260 261 specific hypermethylated and hypomethylated CpG probes for each cell/tissue type of interest. Using this signature, we applied a non-negative least squares method to 262 263 deconvolute our serum and tissue cohort using the standalone program provided by Moss 264 and colleagues ⁵⁰. We then normalized the percentages generated by the standalone 265 program for each cell type/PT-tissue from 0 to 100 by serum.

266 **DNA methylation exploratory analysis (unsupervised analysis)**

In order to evaluate the DNA methylation profile in the serum from patients with distinct tumor types and non-neoplastic brain diseases, we performed a genome-wide Principal Component Analysis (PCA) across the samples (N=147) using the function *prcomp* (version 3.6.0). Consensus clustering was determined by k-means clustering of euclidean distance from the *ConsensusClusterPlus* (version 1.48.0) package.

272 Supervised analysis

We also performed an epigenome-wide differential analysis across the serum from 10 patients with PT and 105 with non-PT conditions patients (4 non-tumor, 114 glioma, 3 meningioma, 1 brain metastasis carcinoma, 1 colloid cyst, and 4 from other CNS necrotic tumors). We used the Wilcoxon rank-sum test to identify differentially methylated probes between two different pairs: PT vs non-PT and functioning vs nonfunctioning PT.

For the comparison between PT and non-PT, probes were considered differentially methylated when the false discovery rate (FDR) was less than .001 and absolute value of the difference of a pair of probe mean methylation between each group was greater than 20%. To identify DMP in the serum that were tissue-specific, we calculated the differences in DNA methylation between the matching serum and tissue, by patient. We then selected probes with less than 5% difference between tissue and serum and considered them tissue-specific.

To validate their PT-specificity, we overlapped PeLB probes with the DNA methylome of an independent cohort consisting of pituitary-, glioma- and meningiomatissue (Figure 1D).

For the comparison between functioning and nonfunctioning, probes were considered differentially methylated when the p-value was less than .01 and absolute

value of the difference of probe mean methylation between each group was greater than20%.

292 Random Forest

293 We used a random forest machine-learning (ML) model for binary classification of the specimens with the aim to classify available cfDNA methylation (from serum) derived 294 295 from patients with PT and non-PT (other neoplastic or non-neoplastic conditions: 296 meningioma, glioma and colorectal carcinoma and nontumor). We first randomly allocated 20% of all samples for the validation set (n = 3 PT; n = 29 Non-PT) only analyzed 297 298 for the assessment of the prediction model accuracy. The remainder serum specimens 299 were used for the feature extraction or training of the random forest model. For developing 300 the model we randomly partitioned the remainder samples into a training (n = 8 PT; n =301 84 Non-PT) and testing set (n = 2 PT; n = 21 Non-PT). We used the function *train* 302 (package *caret* version 6.0.82) in CRAN, with 5000 trees, and 10 fold cross validation to 303 generate our model. When testing the model, we used an output of 50% probability as a 304 cut-off for classification.

305 Based on this result, we adopted the default PeLB score cutoff value of 50 to 306 determine whether a patient had PT. We evaluated the performance of the prediction by 307 applying the ML model on the validation set.

- 308 **Probe annotation**
- CpG probes were mapped to their CpG genomic location as CpG islands (CGI),
 shores, shelves, and open sea regions as previously defined ^{52–55}.
- 311 Statistical analysis

- 312 All processing and statistical analyses were done in R (3.6.1). Wilcoxon rank-sum test
- and multiple testing adjustments (e.g. FDR) were used to identify differentially
- 314 methylated probes (DMP) as stated in the previous sections.
- 315 Supplementary information

316 Acknowledgements

- 317 The authors are grateful to the HFHS patients who consented to the usage of PT for
- 318 research purposes. We thank Nancy Takacs and Heather Mengel for their
- 319 administrative support; Kevin Nelson for the collection, handling and maintenance of the
- 320 tumor bank at the Hermelin Brain Tumor Center; Andrea Transou for tumor pathology
- 321 processing; Laura A. Hasselbach for DNA extraction; Daniel Weisenberger and team at
- 322 USC Epigenome Center for assistance with DNA methylation profiling (HFHS support);
- 323 Susan MacPhee for proofreading the manuscript.

324 Funding

- 325 This work was supported by the Henry Ford Health System, Department of
- 326 Neurosurgery, and the Hermelin Brain Tumor Center. MSM and MC are supported by
- 327 the São Paulo Research Foundation (FAPESP), Brazil (#16/11039-3; #17/10357-
- 328 4,#14/03989-6); AVC and KPA by Henry Ford Hospital (A30935, A30957; GME
- 329 202199); LMP, HN, AD, MW, and AM by the National Institutes of Health
- 330 (R01CA222146), HN, TSS, TMM, LMP, and AD are supported by the Department of
- 331 Defense (CA170278).

332 Author contributions

333 Overall concept and coordination of the study: AVC, JR, HN, KPA; retrieval of publicly

available molecular and clinical data: KPA, MW, AVC; Bioinformatic and statistical

- analyses: MW, TSS, TMM, MSM, HN and input from LMP; HFHF cohort: pathology
- review AM, DC; molecular data generation: TMM, AD; the manuscript was written by
- 337 AVC, HN, MW and intellectual contribution from JS, TM, SK, TW. All authors
- 338 contributed to the revision of the manuscript.

339 Data availability

- 340 The data is available under the accession code GSEXXXX. All the other data supporting
- 341 the findings of this study are available within the article and supplemental information
- 342 and from the corresponding author upon reasonable request.

343 **Competing interests**

344 The authors declare to have no competing interests.

345 Footnotes

- 346 These authors contributed equally as first authors: Michael Wells, Karam P. Asmaro,
- 347 Thais S. Sabedot, Tathiane M. Malta, and Maritza S. Mosella. These authors
- 348 contributed equally as senior authors: Houtan Noushmehr, Ana Valeria Castro

349 **Contributor information**

- 350 Ana Valeria Castro, Email: acastro1@hfhs.org
- 351 Houtan Noushmehr, Email:hnoush1@hfhs.org

353 TABLE LEGENDS

Table 1- Summary of clinicopathological features of patients included in this study.

355 FIGURE LEGENDS

356 Figure 1: Genome-wide DNA methylation profile of pituitary serum cfDNA.

357 Identification of tissue-specific probes that distinguish pituitary serum from non-pituitary 358 serum specimens (Pituitary-tumor specific Epigenetic Liguid-biopsy or PeLB probes). 359 (A) PCA of the mean methylation of pituitary tumors and non-pituitary tumors (glioma, 360 meningioma and colorectal carcinoma) and controls (nontumor conditions). (B) Heatmap depicting the methylation levels of PeLB probes across the entire serum 361 362 cohort (n=107); (C) Heatmap highlights the methylation levels of PeLB probes across 363 pituitary samples and overlapping clinicopathological annotations such as functional and 364 invasion status, transcription factor-related adenohypophyseal cell lineage. (D) The t-365 Distributed Stochastic Neighbor Embedding (t-SNE) plot depicts the overlap of PeLB 366 probes with the methylome of serum specimens from patients harboring pituitary tumors 367 and of the tissue methylome from PT and other CNS tumors (glioma, meningioma). (E) 368 Workflow of sample partitioning of serum cohort for training, testing, and validation used 369 in the random forest analysis to distinguish pituitary tumors from non-pituitary tumors 370 (colorectal carcinoma, glioma, meningiomas). Each test tube represents 10% of the 371 samples. (F) Boxplot of the PeLB score results from the validation set. The dotted line at 372 50% represents the cutoff used for classification into pituitary tumors and non-pituitary 373 samples.

Figure 2: Supervised analysis to identify tissue-specific probes that distinguish
 serum originated from functioning pituitary tumor from those from nonfunctioning
 PT (Functioning <u>Pituitary-tumor specific Epigenetic Liquid-biopsy-PeLB or Func-</u>
 PeLB).

(A) Heatmap displays the methylation levels of the 70 Func-PeLB differentially methylated
probes (DMP) in the serum of nontumor and tumor pituitary specimens. (B) Heatmap
displays the 22 Func-PeLB porbes that overlap with the 450K array in nontumor and
pituitary tumor tissue (C) PCA of pituitary tumor tissue from an independent cohort using
the 22 Func-PeLB probes showing that they segregate samples based on functional

status in both tissue and serum. (D) Box plots of serum (left) and tissue (right) mean
 methylation for each PT (functioning and nonfunctioning) and nontumors samples.

385

386 SUPPLEMENTAL INFORMATION

387 **Supplemental Table 1** - (A) Distribution of the number of the most variant methylated

388 probes in the serum and in the pituitary tumor tissue according to their genomic context

and CpG location. (B) Distribution of the number of differentially methylated probes

390 (PeLB and Func-PeLB) according to their genomic context and CpG location.

391

392 Supplemental Figure 1 - (A) Cell-free DNA concentration in the serum derived from

393 patients with nontumor and tumor conditions. (B) Cell-free DNA concentration in the

394 serum of patients with pituitary tumors (PT) according to function and invasion status.

395 (C) Deconvolution of serum in relation to cell composition from control or pituitary tumor

396 patients. (D) Workflow displaying the selection criteria of pituitary tumor- and

397 functioning-specific methylated probes from the supervised analysis between PT and

non-PT (right) and Functioning and nonfunctioning PT (left) in the serum. (E) Heatmap

399 displaying the genome-wide methylation profile across PT tissue-specimens.

400

401

- 403 Bibliography
- 1. Megnis, K. *et al.* Evaluation of the possibility to detect circulating tumor DNA from
- 405 pituitary adenoma. *Front Endocrinol (Lausanne)* **10**, 615 (2019).
- 406 2. Mouliere, F. et al. High fragmentation characterizes tumour-derived circulating
- 407 DNA. *PLoS ONE* **6**, e23418 (2011).
- 408 3. Jiang, P. & Lo, Y. M. D. The Long and Short of Circulating Cell-Free DNA and the
- Ins and Outs of Molecular Diagnostics. *Trends Genet.* **32**, 360–371 (2016).
- 410 4. Heitzer, E. & Speicher, M. R. One size does not fit all: Size-based plasma DNA
- 411 diagnostics. *Sci. Transl. Med.* **10**, (2018).
- 412 5. Shen, S. Y. et al. Sensitive tumour detection and classification using plasma cell-
- 413 free DNA methylomes. *Nature* **563**, 579–583 (2018).
- 414 6. Kim, H., Wang, X. & Jin, P. Developing DNA methylation-based diagnostic
 415 biomarkers. *J. Genet. Genomics* 45, 87–97 (2018).
- 416 7. Wang, J. & Bettegowda, C. Applications of DNA-Based Liquid Biopsy for Central
- 417 Nervous System Neoplasms. J. Mol. Diagn. **19**, 24–34 (2017).
- 8. Best, M. G. *et al.* Liquid biopsies in patients with diffuse glioma. *Acta Neuropathol.* **129**, 849–865 (2015).
- 420 9. Adamczyk, L. A. et al. Current Understanding of Circulating Tumor Cells Potential
- 421 Value in Malignancies of the Central Nervous System. *Front. Neurol.* **6**, 174 (2015).
- 422 10. Saenz-Antoñanzas, A. et al. Liquid biopsy in glioblastoma: opportunities,
- 423 applications and challenges. *Cancers (Basel)* **11**, (2019).
- 424 11. Bos, M. K. *et al.* Whole exome sequencing of cell-free DNA A systematic review
- 425 and Bayesian individual patient data meta-analysis. *Cancer Treat. Rev.* 83, 101951
- 426 (2020).

- 427 12. Koeppel, F. *et al.* Whole exome sequencing for determination of tumor mutation
- load in liquid biopsy from advanced cancer patients. *PLoS ONE* **12**, e0188174
- 429 (2017).
- 430 13. Neou, M. *et al.* Pangenomic classification of pituitary neuroendocrine tumors.
- 431 *Cancer Cell* (2019). doi:10.1016/j.ccell.2019.11.002
- 432 14. Bi, W. L. et al. Landscape of genomic alterations in pituitary adenomas. Clin.
- 433 *Cancer Res.* **23**, 1841–1851 (2017).
- 434 15. Song, Z.-J. *et al.* The genome-wide mutational landscape of pituitary adenomas.
- 435 *Cell Res.* **26**, 1255–1259 (2016).
- 436 16. Ling, C. *et al.* A pilot genome-scale profiling of DNA methylation in sporadic
- 437 pituitary macroadenomas: association with tumor invasion and histopathological
- 438 subtype. *PLoS ONE* **9**, e96178 (2014).
- 439 17. Kober, P. *et al.* DNA methylation profiling in nonfunctioning pituitary adenomas.
- 440 *Mol. Cell. Endocrinol.* **473**, 194–204 (2018).
- 18. Salomon, M. P. *et al.* The Epigenomic Landscape of Pituitary Adenomas Reveals
- 442 Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and
- 443 Endocrine-Inactive Subtypes. *Clin. Cancer Res.* **24**, 4126–4136 (2018).
- 19. Duong, C. V. et al. Quantitative, genome-wide analysis of the DNA methylome in
- sporadic pituitary adenomas. *Endocr. Relat. Cancer* **19**, 805–816 (2012).
- 446 20. Capper, D. et al. DNA methylation-based classification of central nervous system
- 447 tumours. *Nature* **555**, 469–474 (2018).
- 448 21. Gu, Y. *et al.* Differential DNA methylome profiling of nonfunctioning pituitary
- 449 adenomas suggesting tumour invasion is correlated with cell adhesion. J

450 *Neurooncol* **129**, 23–31 (2016).

451 22. Zhou, Y., Zhang, X. & Klibanski, A. Genetic and epigenetic mutations of tumor

- 452 suppressive genes in sporadic pituitary adenoma. *Mol. Cell. Endocrinol.* **386,** 16–33
- 453 (2014).

454 23. Torregrosa-Quesada, M. E. et al. How Valuable Is the RT-qPCR of Pituitary-

455 Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor

456 Subtypes According to the New WHO 2017 Criteria? *Cancers (Basel)* **11**, (2019).

457 24. Moran, S. et al. Epigenetic profiling to classify cancer of unknown primary: a

458 multicentre, retrospective analysis. *Lancet Oncol.* **17**, 1386–1395 (2016).

459 25. Hoadley, K. A. *et al.* Cell-of-Origin Patterns Dominate the Molecular Classification

460 of 10,000 Tumors from 33 Types of Cancer. *Cell* **173**, 291-304.e6 (2018).

461 26. Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and

462 pathways of progression in diffuse glioma. *Cell* **164**, 550–563 (2016).

463 27. Sahm, F. *et al.* DNA methylation-based classification and grading system for

464 meningioma: a multicentre, retrospective analysis. *Lancet Oncol.* **18**, 682–694

465 (2017).

466 28. Ferraresso, S. *et al.* DNA methylation profiling reveals common signatures of

467 tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large
468 B-cell Lymphoma. *Sci. Rep.* 7, 11591 (2017).

469 29. Mosella, M. S. *et al.* DNA Methylation-based Signatures Classify Sporadic Pituitary

470 Tumors According to Clinicopathological Features. *BioRxiv* (2020).

471 doi:10.1101/2020.04.25.061903

472 30. Lokk, K. et al. DNA methylome profiling of human tissues identifies global and

tissue-specific methylation patterns. *Genome Biol.* **15**, r54 (2014).

- 474 31. Yang, X., Gao, L. & Zhang, S. Comparative pan-cancer DNA methylation analysis
- 475 reveals cancer common and specific patterns. *Brief. Bioinformatics* **18**, 761–773
- 476 (2017).
- 477 32. Hao, X. *et al.* DNA methylation markers for diagnosis and prognosis of common
- 478 cancers. *Proc Natl Acad Sci USA* **114**, 7414–7419 (2017).
- 33. Widschwendter, M. *et al.* Methylation patterns in serum DNA for early identification
 of disseminated breast cancer. *Genome Med.* 9, 115 (2017).
- 481 34. Constâncio, V. *et al.* Early detection of the major male cancer types in blood-based

482 liquid biopsies using a DNA methylation panel. *Clin. Epigenetics* **11**, 175 (2019).

- 483 35. Kang, S. et al. CancerLocator: non-invasive cancer diagnosis and tissue-of-origin
- 484 prediction using methylation profiles of cell-free DNA. *Genome Biol.* **18**, 53 (2017).
- 485 36. Noushmehr, H. *et al.* Detection of glioma and prognostic subtypes by non-invasive
- 486 circulating cell-free DNA methylation markers. *BioRxiv* (2019). doi:10.1101/601245
- 487 37. Mete, O. & Lopes, M. B. Overview of the 2017 WHO classification of pituitary
- 488 tumors. *Endocr. Pathol.* **28**, 228–243 (2017).
- 489 38. Raverot, G. et al. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A
- 490 Prospective Study Using a Five-Tiered Classification. J. Clin. Endocrinol. Metab.
- 491 **102**, 3368–3374 (2017).
- 492 39. Fernández-Balsells, M. M. *et al.* Natural history of nonfunctioning pituitary
- 493 adenomas and incidentalomas: a systematic review and metaanalysis. *J. Clin.*
- 494 *Endocrinol. Metab.* **96**, 905–912 (2011).
- 495 40. Vasiljevic, A., Jouanneau, E., Trouillas, J. & Raverot, G. Clinicopathological

- 496 prognostic and theranostic markers in pituitary tumors. *Minerva Endocrinol.* **41**,
- 497 377–389 (2016).
- 498 41. Selman, W. R., Laws, E. R., Scheithauer, B. W. & Carpenter, S. M. The occurrence
- 499 of dural invasion in pituitary adenomas. *J. Neurosurg.* **64**, 402–407 (1986).
- 42. Asioli, S. et al. Validation of a clinicopathological score for the prediction of post-
- 501 surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from
- 502 a tertiary care centre. *Eur. J. Endocrinol.* **180**, 127–134 (2019).
- 43. Trouillas, J. et al. A new prognostic clinicopathological classification of pituitary
- adenomas: a multicentric case-control study of 410 patients with 8 years post-
- 505 operative follow-up. *Acta Neuropathol.* **126**, 123–135 (2013).
- 506 44. Melmed, S. Pituitary-Tumor Endocrinopathies. *N. Engl. J. Med.* 382, 937–950
 507 (2020).
- 508 45. Nunes, S. P. *et al.* Subtyping lung cancer using DNA methylation in liquid biopsies.
 509 *J. Clin. Med.* 8, (2019).
- 46. Roy, D. & Tiirikainen, M. Diagnostic power of DNA methylation classifiers for early
 detection of cancer. *Trends Cancer* 6, 78–81 (2020).
- 47. Micko, A. S. G., Wöhrer, A., Wolfsberger, S. & Knosp, E. Invasion of the cavernous
- 513 sinus space in pituitary adenomas: endoscopic verification and its correlation with
- an MRI-based classification. *J. Neurosurg.* **122**, 803–811 (2015).
- 48. Knosp, E., Steiner, E., Kitz, K. & Matula, C. Pituitary adenomas with invasion of the
- 516 cavernous sinus space: a magnetic resonance imaging classification compared
- 517 with surgical findings. *Neurosurgery* **33**, 610–7; discussion 617 (1993).
- 518 49. Gallardo-Gómez, M. et al. A new approach to epigenome-wide discovery of non-

- 519 invasive methylation biomarkers for colorectal cancer screening in circulating cell-
- 520 free DNA using pooled samples. *Clin. Epigenetics* **10**, 53 (2018).
- 521 50. Moss, J. et al. Comprehensive human cell-type methylation atlas reveals origins of
- 522 circulating cell-free DNA in health and disease. *Nat. Commun.* **9**, 5068 (2018).
- 523 51. Triche, T. J., Weisenberger, D. J., Van Den Berg, D., Laird, P. W. & Siegmund, K.
- 524 D. Low-level processing of Illumina Infinium DNA Methylation BeadArrays. *Nucleic*525 *Acids Res.* 41, e90 (2013).
- 526 52. Zhou, W., Laird, P. W. & Shen, H. Comprehensive characterization, annotation and
- 527 innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res.*
- 528 **45**, e22 (2017).
- 53. Gardiner-Garden, M. & Frommer, M. CpG islands in vertebrate genomes. *J. Mol. Biol.* **196**, 261–282 (1987).
- 531 54. Sandoval, J. *et al.* Validation of a DNA methylation microarray for 450,000 CpG
 532 sites in the human genome. *Epigenetics* 6, 692–702 (2011).
- 533 55. Takai, D. & Jones, P. A. The CpG island searcher: a new WWW resource. *In Silico* 534 *Biol (Gedrukt)* **3**, 235–240 (2003).





Н

Pituitary Tissue - Functioning PeLB (Func-PeLB)

DNA meth 0.6 0.4 0.2 CPG Location Island Shore Shelf

Open Sea Genomic Location gene.body intergenic promoter Enhancer enhancer Functional Status Nonfunctioning Functioning Invasion Status Invasive Noninvasive NA

2017 WHO Classification Densely.mammotroph Corticotroph Mixed Gonadotroph Lactotroph Null cell Gender Male Female Age 20-40 40-60 60-80

Non Tumor

Functioning PT
 Nonfunctioning PT

Feature	Nontumor (n=4)	NFPT (n=9)	FPT (n=4)
Gender			
Female	1	3	1
Male	2	6	3
Unknown	1	0	0
Age at surgery (years)			
Median (Lower and upper quartile)	31 (22-60)	65(57-68)	52(46-57)
2017 WHO/Hormone staining			
Gonadotroph/LH and/or FSH	-	4	-
Null Cell	-	5	-
Corticotroph/ACTH	-	-	1
Mixed/GH/PRL/TSH	-	-	1
Lactotroph/PRL	-	-	1
Densely lactotroph/PRL	-	-	1
Invasion status			
Invasive	-	5	2
Noninvasive	-	4	2
Size			
Micro_<1cm	-	0	1
Macro_≥1-4cm	-	7	2
Giant_≥4cm	-	2	1

Table 1- Summary of the clinicopathological features from patients harboring pituitary tumors and nontumor conditions (serum)

Legend - FPT: Functioning pituitary tumor. ACTH: Adrenocorticotropic hormone; GH: Growth hormone; PRL: prolactin; LH: luteinizing hormone; FSH: follicle stimulating hormone